Regen Biopharma secures $1.39M net financing via $1.5M note, settles ChemDiv lawsuit for $800K

Regen BioPharma Inc

Issued $1.5M promissory note to Coventry Enterprises LLC; net proceeds $1.39M after $75K OID and $35K fees.
Note carries 5% guaranteed interest, matures July 2022, convertible only upon default.
Paid $800K to ChemDiv to settle lawsuit; settlement includes release of claims and protects IP.
CEO David Koos reports progress: current SEC filings, $1.905M licensing revenue in Q2 2021, revived patents.
Goals include settling all convertible notes, hiring CSO, and seeking OTCQB listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.